TickerTalks
Browse all tickers →
TickerTalks›$AZTA
AZAZTA

Azenta, Inc.

$AZTA·$1.2B·Medical - Instruments & Supplies·Healthcare
$26.71+5.0%YTD-20.1%1Y-16.3%
Mentions · last 7 days
2026-07-09: 2 posts2026-07-10: 1 posts2026-07-11: 4 posts2026-07-12: 2 posts2026-07-13: 1 posts2026-07-14: 0 posts2026-07-15: 1 posts12+9%
Price updated 9h ago·X counts updated 9h ago
AZAZTA
$AZTAAzenta, Inc.
$26.71+4.99%12 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AZTA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptEvent coming upAI verdict · as of 2026-07-14

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Life-sciences tools turnaround shedding B Medical while multiple law firms open investigations.

Azenta provides sample-management, genomics-services, and life-sciences product-and-services solutions — a real franchise that has been in the middle of a multi-year strategic restructure. The recent print pattern is mixed and getting worse: fiscal Q2 EPS was -$0.04 vs $0.10 expected (-140% miss), fiscal Q1 $0.09 vs $0.11 (small miss), Q4 $0.21 vs $0.19 (+11%), Q3 $0.19 vs $0.13 (+46%).

  • Consensus expects a meaningful recovery — revenue from $600M this year to $684M in year four, with EPS from $0.45 to $1.30 — a real inflection embedded in the model.
  • Reported quarterly EPS in the quarterly-financials feed shows lumpy impairment-adjacent items (-$3.49, -$0.34, +$1.03, -$1.15).
  • Two defining events in the window: Azenta completed the sale of B Medical Systems (a strategic-simplification move that centers the company on the core sample-management franchise), and multiple Pomerantz Law Firm investor alerts investigating claims on behalf of Azenta investors — three separate investigation notices hit the tape.
  • Coverage in-window frames AZTA as up 5.4% and "still undervalued" per GF Value.
  • Insider activity is not in the bundle.
  • There is no X sentiment sample for AZTA in the window.
  • Next reset is the August 4 fiscal Q3 print — consensus wants $0.10 EPS.

The operating story is a real turnaround with a specific simplification catalyst (B Medical divestiture) but with a live legal-probe overhang that dampens near-term flows. Watch guide reset, sample-management segment growth, and any material investigation-related developments.

What to watch: August 4 fiscal Q3 print vs $0.10 EPS consensus; guide reset post-B Medical sale; sample-management segment growth; any development in the Pomerantz-flagged investigations.

On the calendar: 2026-08-04 — fiscal Q3 earnings (consensus EPS $0.10)

Read the AI verdict + X sentiment for $AZTA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides biological sample storage, genomics sequencing services, and automated lab equipment to pharma and biotech researchers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $AZTA.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $AZTA

Neutral — Provides biological sample storage, genomics sequencing services, and automated lab equipment to pharma and biotech researchers; end markets and revenue mix have limited overlap with the hospital supply simplification and prime vendor consolidation trend.

Industry benchmark

8-name peer basket
+11.5%YTD
+17.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-0.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-2.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-10.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
44.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$-0.04$0.10-140.0%
Q4 2025Feb 4, 2026$0.09$0.11-18.2%
Q3 2025Nov 21, 2025$0.21$0.19+10.8%
Q2 2025Aug 5, 2025$0.19$0.13+46.2%
Next earningsTue, Aug 4·consensus EPS $0.10

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$144.8M+1.0%42.8%-10.6%$-3.49$4.8M
Q1 FY26$148.6M+0.8%42.9%-3.3%$-0.34$14.7M
Q4 FY25$159.2M+5.7%45.4%1.8%$1.03$-5.7M
Q3 FY25$143.9M-0.2%47.1%1.1%$-1.15$15.0M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$600.5M$589.6M – $603.8M$0.45$0.44 – $0.454
FY27$629.5M$618.1M – $633.1M$0.61$0.60 – $0.624
FY28$675.0M$662.8M – $678.8M$0.85$0.80 – $0.894
FY29$683.5M$671.1M – $687.4M$1.30$1.27 – $1.312
FY30$742.8M$729.4M – $747.0M$1.76$1.72 – $1.772

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.42%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+19.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-5.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 40.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 18William L CornogDirector10.0K sh$164K
+ 10 other (9 awards · 1 inkind) in window

See when $AZTA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 88-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary

Azenta, Inc. (AZTA) completed the acquisition of B Medical Systems S.à r.l. from Thelema S.à r.l. on July 1, 2026. To facilitate closing, Azenta Germany GmbH provided Thelema a $35 million vendor loan at 6.0% per annum, secured by a pledge over 100% of B Medical Systems' equity, maturing 3 months after funding — a related-party transaction approved by the Audit Committee (Thelema is majority owned by VP/B Medical Systems CEO Luc Provost). The acquisition is complete with B Medical Systems now a wholly-owned subsidiary; the $35M vendor loan is a short-term bridge expected to be refinanced.

3New insider — initial holdingsApr 163
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for AZTA on 2026-04-16, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 78-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

AZTA disclosed a personnel change (8-K Item 5.02, dated 2026-04-07). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KMaterial agreementMar 48-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
8-KOfficer or director changeFeb 28-K — Item 5.02: Officer or director change
8-KShareholder voteJan 298-K — Item 5.07: Shareholder vote
+ 10 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Azenta Completes Sale of B Medical Systemsprnewswire.com·8d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAprnewswire.com·42d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAglobenewswire.com·44d agoAzenta Inc (AZTA) Stock Up 5.4% and Still Undervalued -- GF Score: 72/100gurufocus.com·48d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTAprnewswire.com·49d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & HumanoidsAI Precision Medicine

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$WST$AVTR$MDLN$QDEL$RGEN$WRBY$PLSE
Voices on X · last 7 days

No standout posts about $AZTA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport